Dr. Boyu Hu, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 127
Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
UT license 10864951-1205 · TX license Q6328 (first issued 2015; canc non-renewal) -
Internal Medicine Physician
PA license MT201156
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 127
- Services billed
- 748
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 285 | 129 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 260 | 21 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 85 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 68 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 13 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Houston, TX | 122 |
| Brukinsa (zanubrutinib) | 99 |
| Calquence (acalabrutinib maleate) | 34 |
| Venclexta (venetoclax) | 26 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Houston, TX | 24 |
| Ondansetron Hcl Other prescribers in Houston, TX | 19 |
| Prochlorperazine Maleate Other prescribers in Houston, TX | 16 |
| Allopurinol Other prescribers in Houston, TX | 14 |
| Prednisone Other prescribers in Houston, TX | 13 |
| Jaypirca (pirtobrutinib) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 29 payments worth $234,319 in total to this clinician.
| Genentech, Inc. | $225,000 |
|---|---|
| Beone Medicines USA, Inc. | $2,924 |
| Beigene USA, Inc. | $2,400 |
| E.r. Squibb & Sons, L.l.c. | $1,918 |
| Genentech USA, Inc. | $1,605 |
| Adc Therapeutics America, Inc. | $216 |
| Pfizer Inc. | $177 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Grant | $225,000 |
|---|---|
| Consulting Fee | $8,514 |
| Food and Beverage | $761 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Dec 9, 2025 | Consulting Fee BRUKINSA · Oncology | $2,599 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Consulting Fee | $1,910 |
| Genentech USA, Inc. Mar 24, 2025 | Consulting Fee Lunsumio; Polivy · BioOncology | $1,605 |
| Beigene USA, Inc. Mar 7, 2025 | Consulting Fee BRUKINSA · Oncology | $2,400 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
| Genentech, Inc. Feb 28, 2025 | Grant | $15,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $549,391 in research payments for these studies, mostly to the institutions running them.
- A phase 3 prospective,multicenter,randomized,open label trial of acalabrutinib plus venetoclax versus venetoclax plus obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
AstraZeneca UK Limited - A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermedi…
Incyte Corporation - Polarix
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.